Imidapril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Imidapril
Accession Number
DB11783
Type
Small Molecule
Groups
Investigational
Description

Imidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Imidapril Hydrochloride7NSF9GG1NU89396-94-1LSLQGMMMRMDXHN-GEUPQXMHSA-N
Categories
UNII
BW7H1TJS22
CAS number
89371-37-9
Weight
Average: 405.4449
Monoisotopic: 405.189985611
Chemical Formula
C20H27N3O6
InChI Key
KLZWOWYOHUKJIG-BPUTZDHNSA-N
InChI
InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
IUPAC Name
(4S)-3-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
SMILES
[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(=O)OCC)C(=O)N1C(=O)N(C)C[C@@]1([H])C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Imidapril.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Imidapril.
AcebutololAcebutolol may increase the hypotensive activities of Imidapril.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Imidapril.
AcemetacinThe therapeutic efficacy of Imidapril can be decreased when used in combination with Acemetacin.
Acetylsalicylic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Acetylsalicylic acid is combined with Imidapril.
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Imidapril.
AldesleukinThe risk or severity of adverse effects can be increased when Imidapril is combined with Aldesleukin.
AlfuzosinAlfuzosin may increase the hypotensive activities of Imidapril.
AliskirenThe risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Imidapril.
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0041907
PubChem Compound
5464343
PubChem Substance
347828133
ChemSpider
4576628
BindingDB
50020400
ChEBI
135654
ChEMBL
CHEMBL317094
PharmGKB
PA452640
Wikipedia
Imidapril
ATC Codes
C09AA16 — Imidapril

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Unknown StatusTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3Unknown StatusTreatmentHigh Blood Pressure (Hypertension) / Microalbuminuria / Type 2 Diabetes Mellitus1
3Unknown StatusTreatmentHypertension,Essential1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.447 mg/mLALOGPS
logP0.74ALOGPS
logP-0.23ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)3.49ChemAxon
pKa (Strongest Basic)5.22ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area116.25 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity103.2 m3·mol-1ChemAxon
Polarizability42.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / N-acyl-L-alpha-amino acids / Alpha amino acid amides / N-acyl ureas / Fatty acid esters / Aralkylamines / Imidazolidinones / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Dicarboximides
show 9 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid or derivatives / N-acyl urea / Fatty acid ester / Ureide / Aralkylamine / Imidazolidinone
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:47 / Updated on October 01, 2018 16:47